Observational studyBMC cancer2019

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.

Gwo-Fuang Ho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.